Dr. Marek Honczarenko

Dr. Marek Honczarenko serves as the company’s Executive Vice President and CSO. He brings more than 25 years of experience in successful drug development, including achievements in all stages of the pharmaceutical lifecycle.

Dr. Honczarenko joined Mallinckrodt as EVP and CSO in September 2025. Before Mallinckrodt, he served since 2023 as Senior Vice President and Head of Global Innovative Medicines Development at Sun Pharmaceutical Industries. At Sun Pharma, he had full responsibility for driving strategy and execution of the specialty medicines pipeline with oversight of clinical development, clinical operations, biostatistics, experimental medicine, pharmacology, translational medicine, data management, quality assurance, and regulatory strategies across all therapeutic areas and geographies.

Prior to Sun Pharma, he was SVP and Head, Development Clinical Sciences, GlaxoSmithKline, responsible for strategies and programs across all Specialty Therapeutic Areas; Vice President and Head, Global Immunology Development, AbbVie; Head of Immunoscience and Fibrosis, Bristol Myers Squibb; Head, Translational Immunology, Pfizer; Medical Director, Rheumatology, Inflammation and Autoimmunity, MedImmune; and Director, Immunobiology and Translational Medicine, Biogen.

Since October 2019, Dr. Honczarenko has served as an Industry Representative for the FDA Arthritis Advisory Committee. He received an MD and PhD summa cum laude from Pomeranian Medical University, Szczecin, Poland, and completed his post-graduate training at the Perelman School of Medicine at the University of Pennsylvania. He then joined the faculty at Boston Children’s Hospital and Harvard Medical School, and served as a Medical Director at Harvard’s Centre for Human Cell Therapies.